Pliant Therapeutics, Inc. (PLRX)
NASDAQ: PLRX · IEX Real-Time Price · USD
11.81
-0.07 (-0.59%)
Apr 26, 2024, 4:00 PM EDT - Market closed
Pliant Therapeutics Stock Forecast
Stock Price Forecast
The 7 analysts with 12-month price forecasts for Pliant Therapeutics stock have an average target of 50.14, with a low estimate of 38 and a high estimate of 63. The average target predicts an increase of 324.56% from the current stock price of 11.81.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for PLRX stock from 7 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '23 | Dec '23 | Jan '24 | Feb '24 | Mar '24 | Apr '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 5 | 5 | 5 | 4 | 4 | 3 |
| Buy | 6 | 6 | 6 | 5 | 5 | 4 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 11 | 11 | 11 | 9 | 9 | 7 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Needham | Needham | Strong Buy Reiterates $38 | Strong Buy | Reiterates | $38 | +221.76% | Apr 10, 2024 |
| Needham | Needham | Strong Buy Reiterates $38 | Strong Buy | Reiterates | $38 | +221.76% | Mar 12, 2024 |
| RBC Capital | RBC Capital | Buy Maintains $50 → $54 | Buy | Maintains | $50 → $54 | +357.24% | Mar 5, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $48 | Strong Buy | Reiterates | $48 | +306.44% | Feb 28, 2024 |
| RBC Capital | RBC Capital | Buy Maintains $53 → $50 | Buy | Maintains | $53 → $50 | +323.37% | Feb 28, 2024 |
Financial Forecast
Revenue This Year
671.16K
from 1.58M
Decreased by -57.52%
Revenue Next Year
2.90M
from 671.16K
Increased by 331.94%
EPS This Year
-3.35
from -2.75
EPS Next Year
-3.54
from -3.35
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 4.2M | 21.0M | 21.0M | 199.8M | 733.5M |
| Avg | 671,160 | 2.9M | 4.7M | 61.8M | 284.4M |
| Low | n/a | n/a | n/a | n/a | 37.5M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 165.8% | 3,028.9% | 624.4% | 4,183.7% | 1,086.5% |
| Avg | -57.5% | 331.9% | 60.9% | 1,225.5% | 360.0% |
| Low | - | - | - | - | -39.3% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -3.02 | -2.79 | -2.92 | -0.76 | 5.13 |
| Avg | -3.35 | -3.54 | -3.92 | -3.24 | -1.16 |
| Low | -3.53 | -4.33 | -5.93 | -5.15 | -4.73 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | - | - |
| Avg | - | - | - | - | - |
| Low | - | - | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.